Trajan Scientific and Medical (Trajan) is now offering clinical diagnostic packing, a reliable outsourced packing solution for hospitals and pathology clinics, enabling them to focus on core business activities, maximizing diagnostic testing revenue and ultimately improving patient care.
With over 30 years experience in pathology supply in Australia and New Zealand, a global supply network, and clean manufacturing facilities, Trajan is well placed to provide a complete end-to-end solution based at newly renovated facilities within Trajan’s Global Corporate Headquarters located in Melbourne, Australia.
Trajan identified the need for a complete packing solution, due to recent changes in 2015 to the Australian Therapeutic Goods Administration (TGA) In-vitro Diagnostic Framework requirements for registration of products used in clinical applications.
By working closely with the Australian diagnostic community to improve this part of their operations, Trajan creates TGA-compliant procedure packs tailored for a range of clinical applications.
Mr David Giddens, Operations Manager, Clinical Diagnostic Packing, says Trajan’s custom procedure packs contain all items in one convenient pack for clinical procedures, they save time for clinicians and is less invasive for patients.
“Using ready-made packs minimizes contamination of contents and facilitates the process of sending samples to the laboratory, improving turnaround times for patient results.” said Mr Giddens.
Chief Executive Officer of Trajan, Mr Stephen Tomisich is keen to develop the company’s capabilities in this medical field, saying it is a logical step while collaborating with healthcare partners.
“This takes us closer to patients and increases the number of roles Trajan can play in making a positive impact on human wellbeing.” said Mr Tomisich.
Photo: Mr David Giddens, Operations Manager, Clinical Diagnostic Packing, at the newly renovated facilities at Trajan Scientific and Medical in Melbourne, Australia.
Clinical Diagnostic Packing
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.